HAIFA, Israel, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has formed a Preeclampsia Steering Committee to advance its PLacental eXpanded (PLX) cell therapies for the treatment of preeclampsia.
"Preeclampsia is an important indication for our PLX-PAD cells. Based on the dire need for a treatment and the potential of our cell therapy in this indication, we have made it a key priority to enter clinical trials for preeclampsia in the near future," stated Pluristem Chairman and CEO Zami Aberman. "The caliber of medical and scientific thought leaders who have joined our Preeclampsia Steering Committee is a testament to the promise of our PLX cell therapy as a potential treatment for this disease."
Preeclampsia Steering Committee Member, Dr. Sibai, who was a moderator on the preeclampsia scientific forum, "Debate and Consensus: Preeclampsia Biomarkers in Clinical Practice, Are we ready?" at the Society for Maternal Fetal Medicine in New Orleans on Feb 5, 2014, commented, "For almost a thousand years, physicians have had no therapy to offer women with preeclampsia. A safe and effective therapy is needed to treat these women and prolong gestation. Pluristem's PLX cells are a unique potential therapy because they originate from the placenta, which plays a key role in preeclampsia."
|Pluristem ' s Preeclampsia Steering Committee:|
|Prof. James M. Roberts, M.D.|
|University of Pittsburgh|
|Professor, Department of Obstetrics, Gynecology and Reproductive Sciences|
|Professor of Epidemiology, Senior Scientist, Magee-Women's Research Institute|
|Prof. George R. Saade, M.D.|
|University of Texas Medical Branch|
|Professor, Division Chief Obstetrics & Gynecology|
|Prof. Baha M. Sibai, M.D.|
|University of Texas Medical School|
|Dr. David Williams, PhD FRCP|
|University College London|
|Honorary Senior Lecturer, Maternal & Fetal Medicine, Institute for Women's Health, Faculty of Population Health Sciences|
|Prof. Simcha Yagel, M.D.|
|Hadassah Medical Center, Israel|
|Head Division of Obstetrics and Gynecology at Hadassah Medical Center|
|Head of the Israeli Association of Placental Study|
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts